NASDAQ$QURE
uniQure NV · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
uniQure reported its financial results for 2019 and highlighted recent progress across its business.
uniQure reported a net loss of $124.2 million for the year ended December 31, 2019. The company held cash and cash equivalents of $377.8 million as of December 31, 2019, which is expected to fund operations into 2022.
- Patient dosing nearly completed in Phase III HOPE-B trial of Etranacogene Dezaparvovec in Hemophilia B.
- First patient procedure in Phase I/II clinical trial of AMT-130 in Huntington’s Disease expected to occur around the end of the first quarter of 2020.
- Strong balance sheet expected to fund operations into 2022.
- Expect to announce top-line data before the end of this year for Phase III HOPE-B study.
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$2.63M
Forward guidance
uniQure anticipates a transformational year in 2020 with new clinical data announcements and advancement of internally discovered investigational gene therapies.
Tailwinds
- Full enrollment achieved in Phase III HOPE-B study of etranacogene dezaparvovec in hemophilia B.
- Top-line data from the HOPE-B study expected before the end of the year.
- Potential best-in-class profile for etranacogene dezaparvovec as a one-time treatment for hemophilia B.
- Patient screening successfully completed in the Phase I/II clinical trial of AMT-130 in Huntington’s disease.
- First procedure in the AMT-130 trial expected around the end of the first quarter of 2020.
Headwinds
- Risk of cessation, delay, or lack of success of ongoing or planned clinical studies.
- Uncertainty regarding the ability to provide top-line data or any further clinical updates and data with respect to the pivotal Phase III study of AMT-061 before the end of 2020.
- Uncertainty regarding the ability to submit a BLA for marketing authorization of etranacogene dezaparvovec in 2021.
- Risks associated with clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization, and intellectual property claims.
- Potential for actual results to differ materially from those anticipated in forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro